Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
A new multicomponent Pseudomonas vaccine 'pyoimmunogen' has been developed. It was tested for safety and immunogenicity by immunization of volunteer donors and burned patients. Immune plasma obtained from volunteers was used for treatment of severe forms of P. aeruginosa infections. Pyoimmunogen was shown to be of low toxicity for apparently healthy humans and to induce specific antibody formation. In 16 out of 20 burned patients it had a beneficial effect on the course of the disease and the period of hospitalization was shortened. As a result of complex treatment involving the use of anti-P. aeruginosa plasma 51 out of 60 patients recovered.
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000494:pharmacology*; D002056:Burns / Q000150:complications / Q000628:therapy; D005069:Evaluation Studies as Topic; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D011550:Pseudomonas aeruginosa / Q000276:immunology*; D012449:Safety
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines